ARTICLE | Company News
Australian Cancer Tech, RESprotect deal
October 4, 2004 7:00 AM UTC
RESprotect granted ACU a North American license to RP101, a chemopotentiator that has completed a Phase I/II trial in metastatic breast, ovarian and pancreatic cancers, as well as small cell and non-s...